Medigen Biotechnology (ROCO:3176) Change In Receivables : NT$-88 Mil (TTM As of Mar. 2024)

View and export this data going back to 2011. Start your Free Trial

What is Medigen Biotechnology Change In Receivables?

Medigen Biotechnology's change in receivables for the quarter that ended in Mar. 2024 was NT$92 Mil. It means Medigen Biotechnology's Accounts Receivable declined by NT$92 Mil from Dec. 2023 to Mar. 2024 .

Medigen Biotechnology's change in receivables for the fiscal year that ended in Dec. 2023 was NT$60 Mil. It means Medigen Biotechnology's Accounts Receivable declined by NT$60 Mil from Dec. 2022 to Dec. 2023 .

Medigen Biotechnology's Accounts Receivable for the quarter that ended in Mar. 2024 was NT$129 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Medigen Biotechnology's Days Sales Outstanding for the three months ended in Mar. 2024 was 46.80.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Medigen Biotechnology's liquidation value for the three months ended in Mar. 2024 was NT$1,265 Mil.

Medigen Biotechnology Change In Receivables Historical Data

The historical data trend for Medigen Biotechnology's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medigen Biotechnology Change In Receivables Chart

Medigen Biotechnology Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Receivables

Get a 7-Day Free Trial

-95.28

2.10

-631.95

383.95

59.95

Medigen Biotechnology Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial															239.59	-51.45	-200.07	71.88	91.94

Medigen Biotechnology Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was NT$-88 Mil.

Medigen Biotechnology (ROCO:3176) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Medigen Biotechnology's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	128.889	/	251.316	*	91
=	46.80

2. In Ben Graham's calculation of liquidation value, Medigen Biotechnology's accounts receivable are only considered to be worth 75% of book value:

Medigen Biotechnology's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	4329.117	-	3446.844	+	0.75 * 128.889	+	0.5 * 571.376
=	1,265

Medigen Biotechnology Change In Receivables Related Terms

Thank you for viewing the detailed overview of Medigen Biotechnology's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Medigen Biotechnology (ROCO:3176) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medigen Biotechnology Corp (ROCO:3176) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Yuancyu Street, 14F, Building No.3,, Nangang District, Taipei, TWN, 11560

Website

https://www.medigen.com.tw

Medigen Biotechnology Corp is a biopharmaceutical company primarily engaged in new drug development, drug discovery, molecular diagnostics, vaccine, and generic drugs. The new drug development business focuses mainly on the clinical stage of drug development and includes PI-88 MUPAFOSTAT for the treatment of liver cancer and OBP-301 treatment using adenovirus targeted to cancer cells only. Drug discovery includes the development of human-native mAbs for therapeutic applications related to infectious diseases. Generic drugs include pharmaceuticals for infectious diseases (antibiotics), contraceptives, nutrition milk powder, vitamin C tablets, dermatologic agents, and eye care products.

Medigen Biotechnology (ROCO:3176) Headlines

No Headlines